Turtle Creek Wealth Advisors LLC Raises Stake in Gilead Sciences, Inc. $GILD

Turtle Creek Wealth Advisors LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 45.0% during the 1st quarter, Holdings Channel reports. The fund owned 13,695 shares of the biopharmaceutical company’s stock after buying an additional 4,251 shares during the quarter. Turtle Creek Wealth Advisors LLC’s holdings in Gilead Sciences were worth $1,909,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GILD. Aviva PLC lifted its stake in Gilead Sciences by 5.4% during the fourth quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock worth $141,978,000 after purchasing an additional 59,782 shares during the last quarter. Life Cycle Investment Partners Ltd purchased a new position in Gilead Sciences in the fourth quarter valued at approximately $1,418,000. Nordea Investment Management AB raised its holdings in Gilead Sciences by 16.5% during the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock worth $630,056,000 after purchasing an additional 726,101 shares in the last quarter. Beacon Investment Advisory Services Inc. raised its holdings in Gilead Sciences by 10.3% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 111,531 shares of the biopharmaceutical company’s stock worth $13,689,000 after purchasing an additional 10,449 shares in the last quarter. Finally, NBC Securities Inc. lifted its position in shares of Gilead Sciences by 150.3% during the 4th quarter. NBC Securities Inc. now owns 17,147 shares of the biopharmaceutical company’s stock worth $2,105,000 after buying an additional 10,296 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on GILD shares. Weiss Ratings lowered shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. Leerink Partners cut their target price on Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Truist Financial reissued a “buy” rating and issued a $157.00 target price (up from $155.00) on shares of Gilead Sciences in a report on Friday, May 8th. Citigroup upped their target price on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Gilead Sciences in a research report on Monday, June 8th. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $158.41.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $131.27 on Friday. Gilead Sciences, Inc. has a one year low of $107.75 and a one year high of $157.29. The stock has a market capitalization of $162.98 billion, a price-to-earnings ratio of 17.88 and a beta of 0.32. The company has a 50-day simple moving average of $129.48 and a 200-day simple moving average of $134.56. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business’s revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the company posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, analysts predict that Gilead Sciences, Inc. will post -0.8 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were issued a $0.82 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s payout ratio is presently 44.69%.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the transaction, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the completion of the transaction, the chief executive officer directly owned 617,567 shares in the company, valued at $81,185,357.82. This represents a 2.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 83,000 shares of company stock valued at $10,824,500. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.